Skip to content

Wearable Noninvasive Positive Pressure Ventilation Device in COPD

Evaluation of the Impact of a Wearable Noninvasive Positive Pressure Ventilation Device on Physical Activity and Quality of Life in Patients With COPD

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03130361
Acronym
VITABREATH
Enrollment
40
Registered
2017-04-26
Start date
2017-01-12
Completion date
2018-01-10
Last updated
2018-10-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-Invasive Ventilation

Brief summary

The objective is to assess the impact of a wearable Noninvasive Positive Pressure Ventilation, on physical activity and quality of life in patients with severe COPD, complaining of dyspnea.

Detailed description

In order to avoid the occurrence of uncomfortable dyspnea, patients with Chronic Obstructive Pulmonary Disease (COPD) are locked in a vicious circle of inactivity and social isolation which profoundly affects their quality of life and prognosis. A new wearable non invasive positive pressure ventilation device has been recently proposed; it can be used by intermittence during or after physical activities for reducing dyspnea or for shortening dyspnea- recovery time. The investigators hypothesize that this system, in reducing the inconvenience caused by dyspnea, would stimulate a more active lifestyle and improve quality of life. Their objective is to assess the impact of this device on physical activity and quality of life in patients with severe COPD, complaining of dyspnea. In this open study with no control group, participants will use the device at their convenience, according to their needs in daily life and for 4 weeks.

Interventions

DEVICENon-Invasive Ventilation

Sponsors

Philips Respironics
CollaboratorINDUSTRY
Icadom
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DEVICE_FEASIBILITY
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
35 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* Patients with stable severe COPD (with FEV1 ≤50% predicted) * Patients with mMRC score \> ou = 2.

Exclusion criteria

* Exacerbate within a month prior. * Using other non invasive ventilation device \> 15h per day. * Have musculoskeletal or neuromuscular problem affecting balance and walking. * Have cognitive problem affecting comprehension of the different évaluations or questionnaires. * Have recently participated in physical training or rehabilitation program (≤ 3 months). * Medical contra-indication to NIV. * Evolutionary pathologies (excluding COPD) may be life-threatening in the short term (1 year) (cancer, neuromuscular disease rapidly changing). * Simultaneously enrolled in an other clinical trial. * Not affiliated to social security. * Person deprived of liberty, major protected by law.

Design outcomes

Primary

MeasureTime frameDescription
Change of daily physical activity measured by actimetryContinuously over a 8-week period (2 weeks before the use of the device, over the 4-week period usinf the device and 2 weeks after the use of the deviceChange of number of steps by day and daily energy expenditure over the 8 week period

Secondary

MeasureTime frameDescription
Change of Transition Dyspnea Index (TDI)baseline and post use of the Vitabreath device at 4th weeksThe TDI assesses change of dyspnea perception from the BDI in each dimensions. Patient will rate score from -6 to +6 (positive score reflect improve of dyspnea and negative score reflect worse dyspnea).
Subjective appréciation of the devicepost use of the Vitabreath device at 4th weeksPatients will rate their appreciation of the device using 3 scale relatives to ease of use, helps recovery shortness of breath, helps to be more active in daily life
Change of Visual Simplified Respiratory Questionnaire (VSRQ) scorebaseline and post use of the Vitabreath device at 4th weeksThe VRSQ represents health related quality of life of COPD patients
Change of Chronic Obstructive Pulmonary Disease Assessment Test (CAT)scoreContinuously over a 8-week period (2 weeks before the use of the device, over the 4-week period usinf the device and 2 weeks after the use of the deviceThe CAT represents health related quality of life of COPD patients
Change of Baseline Dyspnea Index (BDI) scorebaseline and post use of the Vitabreath device at 4th weeksThe BDI represents importance and impact of dyspnea in daily life of COPD patients. The BDI is one of dyspnea parameters (questionnaire). Three dimension questions include; 1.effect of daily function on dyspnea, 2. effect of magnitude of task on dyspnea and 3. effect of magnitude off effort on dyspnea.
Change of Modified Medical Research Council Questionnaire (mMRC) scorebaseline and post use of the Vitabreath device at 4th weeksThe mMRC is one of dyspnea parameters

Other

MeasureTime frameDescription
Weightbaseline and post use of the Vitabreath device at 4th weeksPatient will indicate their weight
Compliance to the deviceEvery week over the 4-week periodDuring a weekly phone call, patients will indicate the daily duration and conditions of use of the device
Number of acute exacerbationUp to 12 months before the date of inclusionExacerbation is defined as changing the respiratory status of the patient relative to the patient's usual state, which requires acute hospitalisation.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026